{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:02:49Z","timestamp":1791478969266,"version":"4.3.4"},"reference-count":45,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Over the past 20 years, long-term cure rates in T-lymphoblastic leukemia\/lymphoma (T-ALL) have improved from 60% to 65% to &gt;80%, largely due to the intensification of chemotherapy regimens. In B-lymphoblastic leukemia\/lymphoma (B-ALL), outcomes have been improved through risk stratification, integrating clinical and demographic features, response to therapy, and disease biology to identify patients more or less likely to respond to conventional treatment, allowing for the use of regimens adapted to relative risk. Unfortunately, in T-ALL, few features have been identified that can independently predict the risk of poor outcomes beyond response to therapy. Accordingly, most cooperative groups do not use disease biology for T-ALL risk stratification. Recently, several T-ALL genomic initiatives have improved understanding of disease biology, enhanced the ability to classify T-ALL into different biological subtypes, and identified genomic alterations that predict outcome independent of response to treatment. Among these biomarkers is a newly defined high-risk \u201cETP [early T-cell precursor]-like\u201d transcriptional subtype, which reclassifies immature T-ALL based on transcriptomic rather than immunophenotypic features; a treatment-refractory \u201cbone-marrow-progenitor-like\u201d leukemia fraction enriched in relapsed\/refractory T-ALL; and intron-mediated noncanonical NOTCH1 dysregulation. The integration of these new biomarkers into clinical treatment holds promise to inform rapid upfront risk stratification, support new targeted therapeutic approaches, and guide future validation and preclinical studies for high-risk T-ALL.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7028","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T16:47:53Z","timestamp":1750265273000},"source":"Crossref","is-referenced-by-count":6,"title":["Genomic Classification of T-Cell Acute Lymphoblastic Leukemia: Current Paradigms and Future Biomarkers"],"prefix":"10.6004","volume":"23","author":[{"given":"Jason","family":"Xu","sequence":"first","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"Division of Oncology and Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"Division of Oncology and Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"N Engl J Med","first-page":"1541","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger SP","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373:1541\u20131552."},{"key":"B2","series-title":"Leukemia","first-page":"1696","article-title":"Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study","volume":"13","author":"Pullen J","year":"1999","unstructured":"Pullen J, Shuster JJ, Link M,  Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999;13:1696\u20131707."},{"key":"B3","series-title":"Blood","first-page":"1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium protocol 91-01","volume":"97","author":"Silverman LB","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK,  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium protocol 91-01. Blood 2001;97:1211\u20131218."},{"key":"B4","series-title":"Lancet","first-page":"61","article-title":"Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy","volume":"337","author":"Rivera GK","year":"1991","unstructured":"Rivera GK, Raimondi SC, Hancock ML,  Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991;337:61\u201366."},{"key":"B5","series-title":"Lancet","first-page":"143","article-title":"Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia","volume":"345","author":"Chessells JM","year":"1995","unstructured":"Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995;345:143\u2013148."},{"key":"B6","series-title":"Lancet Oncol","first-page":"147","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith E","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M,  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10:147\u2013156."},{"key":"B7","series-title":"Blood","first-page":"1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) study AALL0434","volume":"124","author":"Wood BL","year":"2014","unstructured":"Wood BL, Winter SS, Dunsmore KP,  T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) study AALL0434. Blood 2014;124(Suppl):Abstract 1."},{"key":"B8","series-title":"Blood","first-page":"2069","article-title":"Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study","volume":"142","author":"Wood BL","year":"2023","unstructured":"Wood BL, Devidas M, Summers RJ,  Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study. Blood 2023;142:2069\u20132078."},{"key":"B9","series-title":"Leukemia","first-page":"17201748","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I,  The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36:17201748."},{"key":"B10","series-title":"Cancer Cell","first-page":"75","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando AA","year":"2002","unstructured":"Ferrando AA, Neuberg DS, Staunton J,  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75\u201387."},{"key":"B11","series-title":"Blood","first-page":"274","article-title":"HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL)","volume":"106","author":"Soulier J","year":"2005","unstructured":"Soulier J, Clappier E, Cayuela JM,  HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005;106:274\u2013286."},{"key":"B12","series-title":"Blood","first-page":"4668","article-title":"The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia","volume":"111","author":"Van Vlierberghe P","year":"2008","unstructured":"Van Vlierberghe P, van Grotel M, Tchinda J,  The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008;111:4668\u20134680."},{"key":"B13","series-title":"Cancer Cell","first-page":"484","article-title":"Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia","volume":"19","author":"Homminga I","year":"2011","unstructured":"Homminga I, Pieters R, Langerak AW,  Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011;19:484\u2013497."},{"key":"B14","series-title":"Int J Mol Sci","first-page":"1388","article-title":"DNA methylation in T-cell acute lymphoblastic leukemia: in search for clinical and biological meaning","volume":"22","author":"Ma\u0107kowska N","year":"2021","unstructured":"Ma\u0107kowska N, Drobna-\u015aledzi\u0144ska M, Witt M, Dawidowska M. DNA methylation in T-cell acute lymphoblastic leukemia: in search for clinical and biological meaning. Int J Mol Sci 2021;22:1388."},{"key":"B15","series-title":"Leukemia","first-page":"1163","article-title":"DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes","volume":"34","author":"Kimura S","year":"2020","unstructured":"Kimura S, Seki M, Kawai T,  DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes. Leukemia 2020;34:1163\u20131168."},{"key":"B16","series-title":"PLoS One","first-page":"e65373","article-title":"Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia","volume":"8","author":"Borss\u00e9n M","year":"2013","unstructured":"Borss\u00e9n M, Palmqvist L, Karrman K,  Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS One 2013;8:e65373."},{"key":"B17","series-title":"Cancer Discov","first-page":"2846","article-title":"Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia","volume":"11","author":"Montefiori LE","year":"2021","unstructured":"Montefiori LE, Bendig S, Gu Z,  Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia. Cancer Discov 2021;11:2846\u20132867."},{"key":"B18","series-title":"J Clin Oncol","first-page":"3282","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore KP","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M,  Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol 2020;38:3282\u20133293."},{"key":"B19","series-title":"Blood","first-page":"159","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey DT","year":"2020","unstructured":"Teachey DT, O\u2019Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 2020;135:159\u2013166."},{"key":"B20","series-title":"Nat Genet","first-page":"1211","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu Y","year":"2017","unstructured":"Liu Y, Easton J, Shao Y,  The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 2017;49:1211\u20131218."},{"key":"B21","series-title":"Nature","first-page":"1082","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"P\u00f6l\u00f6nen P","year":"2024","unstructured":"P\u00f6l\u00f6nen P, Di Giacomo D, Seffernick AE,  The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature 2024;632:1082\u20131091."},{"key":"B22","series-title":"Leukemia","first-page":"1358","article-title":"Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia","volume":"32","author":"De Bie J","year":"2018","unstructured":"De Bie J, Demeyer S, Alberti-Servera L,  Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. Leukemia 2018;32:1358\u20131369."},{"key":"B23","series-title":"Blood","first-page":"2463","article-title":"Single cell RNA-seq reveals developmental plasticity with coexisting oncogenic and immune evasion programs in ETP-ALL","volume":"137","author":"Anand P","year":"2021","unstructured":"Anand P, Guillaumet-Adkins A, Dimitrova V,  Single cell RNA-seq reveals developmental plasticity with coexisting oncogenic and immune evasion programs in ETP-ALL. Blood 2021;137:2463\u20132480."},{"key":"B24","series-title":"Nat Cancer","first-page":"102","article-title":"A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia","volume":"6","author":"Xu J","year":"2025","unstructured":"Xu J, Chen C, Sussman JH,  A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia. Nat Cancer 2025;6:102\u2013122."},{"key":"B25","series-title":"J Clin Oncol","first-page":"21062118","article-title":"Children\u2019s Oncology Group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey DT","year":"2022","unstructured":"Teachey DT,  Devidas M,  Wood BL,  Children\u2019s Oncology Group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol 2022;40:21062118."},{"key":"B26","series-title":"Blood","first-page":"313","article-title":"Genomic biomarkers of poor outcome in patients with T-cell lymphoblastic lymphoma","volume":"144(Suppl 1)","author":"Newman H","year":"2024","unstructured":"Newman H, Uppuluri L, Shraim R,  Genomic biomarkers of poor outcome in patients with T-cell lymphoblastic lymphoma. Blood 2024;144(Suppl 1):313. Abstract 614."},{"key":"B27","series-title":"Blood","first-page":"1273","article-title":"Single-cell pan-cancer analysis reveals treatment resistance stem\/progenitor-like subpopulation in the high-risk pediatric leukemia","volume":"140","author":"Chen C","year":"2022","unstructured":"Chen C, Xu J, Vincent TL,  Single-cell pan-cancer analysis reveals treatment resistance stem\/progenitor-like subpopulation in the high-risk pediatric leukemia. Blood 2022;140:1273\u20131274."},{"key":"B28","series-title":"Cancer Res","first-page":"5360","article-title":"S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma","volume":"77","author":"Chow KH","year":"2017","unstructured":"Chow KH, Park HJ, George J,  S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma. Cancer Res 2017;77:5360\u20135373."},{"key":"B29","series-title":"Leukemia","first-page":"735","article-title":"A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia","volume":"34","author":"Elsayed AH","year":"2020","unstructured":"Elsayed AH, Rafiee R, Cao X,  A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia 2020;34:735\u2013745."},{"key":"B30","series-title":"Nature","first-page":"433","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng SWK","year":"2016","unstructured":"Ng SWK, Mitchell A, Kennedy JA,  A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 2016;540:433\u2013437."},{"key":"B31","series-title":"Blood","first-page":"2198","article-title":"Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia","volume":"139","author":"Chen C","year":"2022","unstructured":"Chen C, Yu W, Alikarami F,  Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood 2022;139:2198\u20132211."},{"key":"B32","series-title":"J Clin Oncol","first-page":"3816","article-title":"Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia","volume":"28","author":"Gutierrez A","year":"2010","unstructured":"Gutierrez A, Dahlberg SE, Neuberg DS,  Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol 2010;28:3816\u20133823."},{"key":"B33","series-title":"Pediatr Blood Cancer","first-page":"846","article-title":"Absence of biallelic TCR\u03b3 deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia","volume":"58","author":"Yang YL","year":"2012","unstructured":"Yang YL, Hsiao CC, Chen HY,  Absence of biallelic TCR\u03b3 deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2012;58:846\u2013851."},{"key":"B34","series-title":"Leukemia","first-page":"1145","article-title":"BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines","volume":"28","author":"Anderson NM","year":"2014","unstructured":"Anderson NM, Harrold I, Mansour MR,  BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia 2014;28:1145\u20131148."},{"key":"B35","series-title":"Nat Med","first-page":"170","article-title":"Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response","volume":"29","author":"Lee SHR","year":"2023","unstructured":"Lee SHR, Yang W, Gocho Y,  Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. Nat Med 2023;29:170\u2013179."},{"key":"B36","series-title":"Blood","first-page":"2750","article-title":"Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia","volume":"130","author":"Serafin V","year":"2017","unstructured":"Serafin V, Capuzzo G, Milani G,  Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. Blood 2017;130:2750\u20132761."},{"key":"B37","series-title":"Leukemia","first-page":"1194","article-title":"Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia","volume":"37","author":"Yoshimura S","year":"2023","unstructured":"Yoshimura S, Panetta JC, Hu J,  Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 2023;37:1194\u20131203."},{"key":"B38","series-title":"Blood","first-page":"3739","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord K","year":"2014","unstructured":"Beldjord K, Chevret S, Asnafi V,  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 2014;123:3739\u20133749."},{"key":"B39","series-title":"J Clin Oncol","first-page":"3545","article-title":"The clinicogenomic landscape of induction failure in childhood and young adult T-cell acute lymphoblastic leukemia","volume":"41","author":"O\u2019Connor D","year":"2023","unstructured":"O\u2019Connor D, Demeulemeester J, Conde L,  The clinicogenomic landscape of induction failure in childhood and young adult T-cell acute lymphoblastic leukemia. J Clin Oncol 2023;41:3545\u20133556."},{"key":"B40","series-title":"PNAS Nexus","first-page":"pgae011","article-title":"Decoding the genetic symphony: profiling protein-coding and long noncoding RNA expression in T-acute lymphoblastic leukemia for clinical insights","volume":"3","author":"Verma D","year":"2024","unstructured":"Verma D, Kapoor S, Kumari S,  Decoding the genetic symphony: profiling protein-coding and long noncoding RNA expression in T-acute lymphoblastic leukemia for clinical insights. PNAS Nexus 2024;3:pgae011."},{"key":"B41","series-title":"Cell","first-page":"649","article-title":"TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms","volume":"66","author":"Ellisen LW","year":"1991","unstructured":"Ellisen LW, Bird J, West DC,  TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649\u2013661."},{"key":"B42","series-title":"J Exp Med","first-page":"2283","article-title":"Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles","volume":"183","author":"Pear WS","year":"1996","unstructured":"Pear WS, Aster JC, Scott ML,  Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996;183:2283\u20132291."},{"key":"B43","series-title":"Science","first-page":"269","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng AP","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W,  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269\u2013271."},{"key":"B44","series-title":"Leukemia","first-page":"2005","article-title":"The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function","volume":"24","author":"Kox C","year":"2010","unstructured":"Kox C, Zimmermann M, Stanulla M,  The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010;24:2005\u20132013."},{"key":"B45","series-title":"Blood","first-page":"3918","article-title":"NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study","volume":"113","author":"Asnafi V","year":"2009","unstructured":"Asnafi V, Buzyn A, Le Noir S,  NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009;113:3918\u20133924."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/7\/article-e257028.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/7\/article-e257028.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/7\/article-e257028.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T12:30:18Z","timestamp":1752150618000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/7\/article-e257028.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7028","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}